Salivary Gland Cancer Clinical Trial
Official title:
Phase II Study of ZD1839 (Iressa®), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor in Patients With Advanced, Recurrent or Metastatic Salivary Gland Cancer (IRUSIRES0198)
Verified date | October 2017 |
Source | M.D. Anderson Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this clinical research study is to learn if ZD1839 (Iressa®, gefitinib can help to shrink or slow the growth of advanced, recurrent, or metastatic salivary gland cancer. The safety of this drug will also be studied.
Status | Completed |
Enrollment | 37 |
Est. completion date | September 2016 |
Est. primary completion date | September 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: 1. Histologically or cytologically confirmed salivary gland carcinoma. 2. Patients with advanced or recurrent salivary gland cancer who are not candidates for curative surgery or radiotherapy. 3. Measurable disease per the RECIST criteria. For disease occurring in previously irradiated field, there must be confirmed progression prior to the date registration and more than three months after completion of radiotherapy 4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2. 5. Prior central nervous system (CNS) involvement by tumor is permissible if previously treated and clinically stable for two weeks after completion of treatment. 6. At least a 2-week recovery from prior therapy toxicity. 7. Provision of written informed consent. 8. Childbearing potential either terminated by surgery, radiation, or menopause, or attenuated by use of an approved contraceptive method (IUD, birth control pills, or barrier device) during and for 3 months after completion of trial therapy. Exclusion Criteria: 1. Known severe hypersensitivity to or any of the excipients of this product. 2. Other coexisting malignancies or malignancies diagnosed within the last 5 years, with the exception of basal cell carcinoma, squamous cell carcinoma of the skin, or cervical cancer in situ. 3. Concomitant use of phenytoin, carbamazepine, rifampicin, phenobarbital, or St John's Wort or CYP3A4 (e.g. itraconazole, ketoconazole) 4. Treatment with a investigational drug within 28 days before Day 1 of trial treatment. 5. Any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer therapy (except alopecia) 6. Incomplete healing from previous surgery. 7. Serum creatinine level greater than CTC grade 2. 8. Women who are pregnant or breast feeding. 9. Prior or other EGFR inhibiting agents. 10. Serum bilirubin greater than 1.25 times the upper limit of reference range (ULRR). 11. Any evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease). 12. Alanine amino transferase (ALT) or aspartate amino transferase (AST) greater than 2.5 times the ULRR if no demonstrable liver metastases or greater than 5 times the ULRR in the presence of liver metastases. 13. Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the trial. 14. Uncontrolled seizure disorder, active neurological disease, or greater than Grade 2 neuropathy. 15. Keratoconjunctivitis sicca or incompletely treated eye infection. 16. Abnormal marrow function as defined as absolute neutrophil count <1,500/ul or platelets <100,000/ul. 17. Second primary malignancy (except in situ carcinoma of the cervix or adequately treated nonmelanomatous carcinoma of the skin or other malignancy treated at least 3 years previously with no evidence of recurrence; prior low grade [Gleason score less than 6] localized prostate cancer is allowed). |
Country | Name | City | State |
---|---|---|---|
United States | University of Texas MD Anderson Cancer Center | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
M.D. Anderson Cancer Center | AstraZeneca |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Response Rate of ZD1839 in Patients With Advanced or Recurrent Salivary Gland Cancer Who Are Not Candidate for Curative Surgery or Radiotherapy | The modified Response Evaluation Criteria in Solid tumors (RECIST) criteria was used for objective tumor response assessment. Complete Response (CR): Disappearance all target lesions; Partial Response (PR): >30% decrease in sum longest diameter (LD) of target lesions, reference baseline sum LD; Progressive Disease (PD): >20% increase in sum LD of target lesions, reference smallest sum LD recorded since treatment started or appearance of one or > new lesions; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, reference smallest sum LD since treatment started. Response rate estimated by Gehan's Phase II clinical trial design. | Every 4 weeks until progressive disease, unacceptable toxicity or patient withdrawal |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03729297 -
Cabozantinib in Advanced Salivary Gland Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT01969578 -
Androgen Deprivation Therapy in Advanced Salivary Gland Cancer
|
Phase 2 | |
Completed |
NCT01703455 -
Activity of Sorafenib in Salivary Gland Cancer
|
Phase 2 | |
Recruiting |
NCT04140526 -
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05010629 -
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT03781986 -
APG-115 in Salivary Gland Cancer Trial
|
Phase 1/Phase 2 | |
Completed |
NCT03319641 -
PSMA-PET Imaging for Advanced ACC/SDC
|
N/A | |
Recruiting |
NCT02012699 -
Integrated Cancer Repository for Cancer Research
|
||
Recruiting |
NCT04028479 -
The Registry of Oncology Outcomes Associated With Testing and Treatment
|
||
Recruiting |
NCT05483374 -
The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers
|
||
Completed |
NCT04291300 -
Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03172624 -
Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
|
Phase 2 | |
Active, not recruiting |
NCT05008237 -
Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study
|
Phase 2 | |
Recruiting |
NCT03360890 -
Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors
|
Phase 2 | |
Not yet recruiting |
NCT05898373 -
Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02069730 -
A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes
|
N/A | |
Recruiting |
NCT04209660 -
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
|
Phase 2 | |
Completed |
NCT01344356 -
Stereotactic Body Radiotherapy for Head and Neck Tumors
|
Phase 4 | |
Completed |
NCT03602079 -
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06091878 -
Gene Expression Profiling in a Validation Cohort of Locally Advanced and Recurrent/Metastatic Salivary Gland Cancers
|